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The performance of a new enzyme immunoassay (EIA) procedure (Abbott Labs.) for cancer antigen 125 (CA 125) met or exceeded the manufacturer's claims for all analytical vanables examined. Overall correlation with results obtained with a radioimmunoassay (AlA) were good. However, near the decision thresholds typically chosen to define a positive result for ovarian carcinoma, EIA results were 10 to 20 arbitrary units/mL less than the RIA results. At specific decision thresholds, therefore, the sensitivities and specificities of the EIA and RIA procedure differed. Adjusting the decision thresholds gave a similar optimum efficiency for each procedure: EIA, 82.9% (decision threshold, 35 units/mL); RIA, 83.4% (decision threshold, 54 units/mL). Receiver-operating characteristic curves showed that the two procedures' ability to distinguish patients with active ovarian carcinoma from those with disease in remission was the same.
The poor prognosis of patients with ovarian carcinoma results in part from the absence of specific early symptoms. This has stimulated the search for a reliable marker of this disease in serum (1). A monoclonal antibody (OC 125) has been developed that reacts with a surface marker, cancer antigen 125 (CA 125), which is expressed on more than 80% of ovarian carcinomas (2,3).' In serum, CA 125 is associated with a high-molecular-mass glycoprotein. With a radioimmunoassay of CA 125, a positive test result (defined as CA 125 >35 arbitrary units/mL) was found in 82% of patients with ovarian carcinomas, 6% of patients with nonmalignant diseases, and 1% of healthy individuals (4, 5).
In general, changes in the concentrations of CA 125 in serum correlate well with disease activity (6-14). Therefore, a positive CA 125 test result for the patient who has completed initial surgery and a first course of chemotherapy may indicate the persistence of disease, obviating the usual "second-look" laparotomy to assess disease status (15). A negative CA 125 result under such circumstances, however, does not always correlate with lack of disease, particularly disease that is only microscopically detectable (8,10,12,14).
CA 125 in serum has been measured by radioimmunoassay (2, 16). Here we report our evaluation of a new enzyme immunoassay (EIA) procedure recently developed for CA 125.
MaterIals and Methods
We obtained 198 serum samples from 82 patients with ovarian neoplasms. Of these, 95 were from patients with active disease and 103 from patients with disease in remission. In all cases, disease status, assessed on the date the sample was obtained, was based on histological assessment of biopsies for patients with active disease. For patients with inactive disease, this assessment was based on lack of disease as evaluated by histological evaluation of biopsy, radiographic studies including computerized axial tomography, and (or) clinical assessment.
CA 125 was doubly measured in each sample: by radioimmunoassay (performed by SmithKline Bio-Science Laboratory, St. Louis, 60064), a simultaneous solid-phase "sandwich"-type immunoassay (17) . In the EIA, beads coated with monoclonal anti-CA 125 are incubated with the specimen and with monoclonal anti-CA 125 conjugated to horseradish peroxidase (EC 1.11.1.7). After incubation, unbound materials are removed by washing and the beads are incubated with o-phenylenediamine substrate containing hydrogen peroxide. The intensity of color formed is proportional to the amount of CA 125 in the sample and is measured spectrophotometrically at 492 nm. Results are expressed in arbitrary units.
Studies of correlations between EJA and RIA results included the following:
#{149} Diagnostic sensitivity, specificity, and efficiency of each procedure (18) , #{149} Split-sample comparisons of all results and of the subset of results near the decision threshold (19), and #{149} Receiver-operating characteristic curves for each test as described by Beck and Schultz (20) .
We also assessed the analytical performance of the EIA procedure by evaluating: #{149} The effect of potential interference from lipemia, bilirubin, and hemolysate, assessed by using interferographs as previously described (21) . The maximum concentrations studied were: hemolysate (as hemoglobin), 10 gIL; bilirubin, 0.6 g/L; lipemia (added Intralipid), 10 g/L.
#{149} The reference interval, evaluated from data on serum samples from 22 normal, nonpregnant women volunteers.
#{149} The detection limit, as determined from 20 replicate analyses of the zero standard (supplied by the manufacturer) by calculating their mean + 2 SD (17) .
Results and Discussion
The distribution, as assessed by histology, of patients with ovarian neoplasms is shown in Table 1 . Of the 82 subjects in this study, 71(87%) had ovarian carcinomas. Figure 1 shows the distribution of CA 125 results for patients with active disease and patients with inactive disease, as measured by the EIA procedure.
To compare CA 125 results obtained by EIA and RIA, we performed a split-sample correlation study. Correlation and range of results were as follows: range (RIA), <7 to 17 549 units/mL; range (EIA), <5 to 18800 units/mL; mean (RIA), 12 ( Although this overall correlation analysis is favorable, we noted that, near the decision thresholds typically used to define a positive CA 125 test, most EJA results were 10 to 20 units/niL less than the corresponding RIA results. Correlation of the 159 samples with CA 125 <100 units/mL gave the following-mean (RIA), 34.6 units/mL; mean (EIA), 19.5 units/niL; m, 0.77; b, -7 units/mL; r, 0.84; S, 15.4 units/niL. For all but three of 142 specimens (98%) the EIA value was less than the RIA value. All of these three specimens were from a single patient.
Because of this 15.1 unitimL difference in means (EIA < RIA), we examined the difference in sensitivity and specificity of these procedures at the decision threshold most commonly used to define a positive test (35 units/mL) for patients with active (Table 2 ) and inactive (Table 3) disease. At this decision threshold the sensitivity of the EIA procedure (75%) is less than the sensitivity either observed here (83%) or reported in other studies (8 1-85%) (4,9,22) for the RIA procedure. As expected, however, the better sensitivity of the RIA procedure was offset by lower specificity as compared with the EIA method (RIA, 82%; EJA, 90%) procedure. The optimal efficiency for the RIA procedure was 83.4% if we used a decision threshold of 54 units/mL. The optimal efficiency for the EIA procedure, 82.9%, was obtained with a decision threshold of 35 units/mL. At these decision thresholds (Tables 2 and 3 ) the sensitivities of the procedures are similar (EIA, 75%; RIA, 74%) and the specificities of the procedures are more nearly the same: EIA, 90%; RIA, 93%. Results for the subgroup of patients with ovarian carcinomas were nearly identical.
Because the efficiency of the two methods was almost identical when the optimal decision threshold was used, we prepared ROC curves (Figure 2 ) to see if either procedure better distinguished active disease from disease in remission. Although the sensitivity and specificity varied, as expected, at particular thresholds, the areas under the two curves were identical, indicating that both tests have equal discriminating power for the presence of active disease vs disease in remission (20) .
We also examined the analytical performance of the EIA procedure. We confirmed the manufacturer's claim that dilution and re-assay are not required if the CA 125 result is <650 units/mL. Only 16 of 198 (8%) of our specimens required dilution and re-assay. The manufacturer states that the detection limit of the EIA procedure is about 5 units/mL; however, we calculated a detection limit of 0.2 units/mL, indicating that the detection limit is better than that stated by the manufacturer. The reference interval for CA 125 in the healthy population measured with the RIA procedure reportedly is 20-40 units/mL (12, 23) , although values >300 units/mL have been observed (24) . We used the EJA procedure to measure CA 125 in 22 healthy nonpregnant female volunteers. The range of results we observed in this group (0-6 urntslmL) was lower than noted in the reports where an RIA procedure had been used.
We assessed the effect of the potential interfering substances lipemia, bilirubin, and hemoglobin, by use of interferographs. We found no effect on this procedure at the concentrations used in this study.
We found the analytical performance of the EIA test for CA 125 to be excellent, and we believe that it can be used as an alternative to the RIA procedure. No overall difference between the EJA or RIA procedures for CA 125 was noted when these were used to discriminate patients with active disease from those with disease in remission. The bias of 15 units/mL (EIA <RIA) produced important differences in the sensitivity and specificity of each test at particular decision thresholds. These differences affect the definition of a positive CA 125 test result in deciding which patients would benefit from second-look laparotomy. In such cases a different decision threshold should be used if the EIA procedure is substituted for the RIA method.
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